We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
For the second consecutive week, the House of Representatives passed a slew of bills addressing the opioid crisis, including one on Friday directing the FDA to assess non-addictive treatment options. Read More
The judge rejected claims that FDA regulations preempt state law and that the companies are not accountable for doctor and pharmacist misconduct. Read More
Public Citizen is urging the FDA to take Takeda’s Uloric and all products containing febuxostat off the market after the recent release of a post-market study claiming the gout treatment poses serious risks to patients and offers no unique benefits compared to other lower-risk medications. Read More
A New York judge refused a request by opioid manufacturers to throw out lawsuits by eight counties, ruling against defenses similar to those offered by opioid makers in pending federal litigation. Read More
The FDA withdrew its draft guidance on analytical studies of biosimilars Thursday and said it plans to issue an amended version that will give sponsors “appropriate flexibility.” Read More
The Trump administration is proposing to change the FDA’s name to the Federal Drug Administration and shift the agency’s food programs to the U.S. Department of Agriculture according to a broad government reform plan released yesterday. Read More
The agency will grant a waiver or reduction of one or more user fees if needed to protect public health, if the assessment would hurt innovation, or if the applicant is a small business submitting its first human drug application. Read More
The European Medicines Agency launched its new online portal for orphan designation applications and is strongly encouraging companies to start using the portal right away, although it will not fully replace the existing submission process until the fall. Read More